BMJ1d
FRI0115 Humira® (Adalimumab): Fifteen Years of Controlled Production and Consistency of Quality Attributes
Background Biologics, in particular monoclonal antibodies (mAbs), transformed treatment of autoimmune diseases such as rheumatoid arthritis (RA) by selectively targeting pathogenesis and modifying ...
BMJ1d
HLA-B27 associated spondyloarthropathy, an autoimmune disease based on crossreactivity between bacteria and HLA-B27?
Academic Medical Centre, University of Amsterdam, Department of Medical Microbiology, the Netherlands Dr J H Ringrose, Department of Medical Microbiology, Academic Medical Centre, AMC L1–160, PO Box ...
BMJ1d
EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis: 2023 update
Introduction Hip and knee osteoarthritis (OA) are increasingly common with a significant impact on individuals and society. Non-pharmacological treatments are considered essential to reduce pain and ...
BMJ2d
Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis
Objective This observational cohort study investigated the impact of biological (b) disease-modifying antirheumatic drugs (DMARDs) on the outcomes of serious infections (SIs) in patients with ...
BMJ3d
Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial
7 National Referral Centre for Rare Systemic Auto-immune Diseases, Cochin Hospital, AP-HP, Paris Descartes University, Paris, France Objectives To evaluate the effect of adding a 10-week treatment of ...
BMJ3d
Baseline predictors of different types of treatment success in rheumatoid arthritis
Objective To perform a comprehensive analysis on predictors of achieving disease activity outcomes by change, response and state measures. Methods We used data from three rheumatoid arthritis (RA) ...
BMJ4d
AB0285 EFFECTIVENESS OF IMMUNOSUPPRESSIVE THERAPY FOR CONNECTIVE TISSUE DISEASE–ASSOCIATED PULMONARY ARTERIAL HYPERTENSION
1 Graduate School of Medicine, The University of Tokyo, Department of Cardiovascular Medicine, Tokyo, Japan 2 Graduate School of Medicine, The University of Tokyo., Department of Therapeutic Strategy ...
BMJ4d
Guidelines for musculoskeletal ultrasound in rheumatology
Dr B Manger, Department of Internal Medicine III, University Erlangen Krankenhausstr 12, D-91054 Erlangen, Germany Newer US techniques, which are currently being evaluated, include colour and power ...
BMJ4d
The association of bone attrition with knee pain and other MRI features of osteoarthritis
Objective: To determine whether bone attrition (flattening or depression of the subchondral bone) was associated with the presence and severity of knee pain and to evaluate the coexistence of ...
BMJ5d
Efficacy of rituximab in primary Sjögren's syndrome with peripheral nervous system involvement: results from the AIR registry
1 Department of Internal Medicine, Hôpital Jean Verdier, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Sud 13, Bondy, France 2 Clinical Research Department, Hôpital Hotel Dieu, ...
BMJ6d
Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies
2 Division of Rheumatology, University of British Columbia, Vancouver, Canada 3 Centre for Health Evaluation and Outcomes Sciences, Providence Health, University of British Columbia, Vancouver, Canada ...
BMJ6d
EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome
Objectives To develop a score for assessment of patients' symptoms in primary Sjögren's syndrome (SS): the EULAR SS Patient Reported Index (ESSPRI). Methods Dryness, pain, somatic and mental fatigue ...